JPMorgan analyst Brian Ossenbeck downgraded RXO Inc. to Underweight from Neutral with a price target of $16, down from $17. The analyst continues to see material risk to consensus estimates, especially in a lower for longer freight rate environment. The downgrade reflects earnings revision risk and cycle positioning, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RXO:
